Sedana Medical AB (publ) (STO:SEDANA)
Sweden · Delayed Price · Currency is SEK 9.55
+0.25 (2.69%)
Nov 4, 2026, 5:29 PM CET
Sedana Medical AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 198.44 | 200.23 | 178.75 | 153.87 | 122.87 | 159.15 | |
Revenue Growth | 0.42% | 12.01% | 16.17% | 25.23% | -22.80% | 12.26% |
Cost of Revenue | 56.41 | 57.52 | 52.61 | 44.89 | 36.79 | 52.45 |
Gross Profit | 142.03 | 142.71 | 126.14 | 108.98 | 86.07 | 106.71 |
Selling, General & Admin | 157.07 | 154.66 | 156.6 | 154.74 | 169.94 | 148.31 |
Research & Development | 20.78 | 20.62 | 20.29 | 20.81 | 19.94 | 19.7 |
Other Operating Expenses | -0.01 | -0.01 | 0.03 | -0.02 | 0.12 | -0.11 |
Operating Expenses | 177.84 | 175.26 | 176.92 | 175.53 | 190.01 | 167.9 |
Operating Income | -35.81 | -32.55 | -50.78 | -66.55 | -103.93 | -61.2 |
Interest Expense | - | -1.45 | -0.18 | -0.22 | -0.26 | -0.24 |
Interest & Investment Income | 30.59 | 3.38 | 16.49 | 15.17 | 3.58 | - |
Currency Exchange Gain (Loss) | -26.81 | -26.64 | 24.52 | -7.42 | 27.68 | 4.07 |
Other Non Operating Income (Expenses) | 0 | 0 | -0 | - | - | - |
Pretax Income | -32.03 | -57.26 | -9.95 | -59.02 | -72.93 | -57.37 |
Income Tax Expense | 2.51 | 1.98 | 0.73 | 0.59 | 0.57 | 0.6 |
Net Income | -34.54 | -59.24 | -10.67 | -59.61 | -73.51 | -57.97 |
Net Income to Common | -34.54 | -59.24 | -10.67 | -59.61 | -73.51 | -57.97 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 99 | 99 | 99 | 99 | 99 | 93 |
Shares Outstanding (Diluted) | 99 | 99 | 99 | 99 | 99 | 93 |
Shares Change | - | - | - | - | 6.85% | 1.54% |
EPS (Basic) | -0.35 | -0.60 | -0.11 | -0.60 | -0.74 | -0.62 |
EPS (Diluted) | -0.36 | -0.60 | -0.11 | -0.60 | -0.74 | -0.62 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -15.93 | -15.18 | -13.99 | -38.58 | -116.17 | -46.41 |
Free Cash Flow Per Share | -0.16 | -0.15 | -0.14 | -0.39 | -1.17 | -0.50 |
Gross Margin | 71.57% | 71.27% | 70.57% | 70.83% | 70.06% | 67.05% |
Operating Margin | -18.04% | -16.26% | -28.41% | -43.25% | -84.59% | -38.45% |
Profit Margin | -17.40% | -29.59% | -5.97% | -38.74% | -59.83% | -36.42% |
Free Cash Flow Margin | -8.03% | -7.58% | -7.82% | -25.07% | -94.55% | -29.16% |
EBITDA | -27.13 | -30.41 | -47.2 | -64.19 | -100.56 | -56.8 |
EBITDA Margin | -13.67% | -15.19% | -26.41% | -41.72% | -81.84% | -35.69% |
D&A For EBITDA | 8.68 | 2.15 | 3.58 | 2.36 | 3.38 | 4.4 |
EBIT | -35.81 | -32.55 | -50.78 | -66.55 | -103.93 | -61.2 |
EBIT Margin | -18.04% | -16.26% | -28.41% | -43.25% | -84.59% | -38.45% |